FibroGen, Inc.
United States
194 articles with FibroGen, Inc.
-
FibroGen to Report First Quarter 2022 Financial Results
4/25/2022
FibroGen, Inc. will announce its first quarter 2022 financial results on Monday, May 9 after the market close.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
4/20/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.
-
FibroGen is tangled up in a Securities Class Action Litigation and Derivative Litigation concerning clinical trial data for its drug Roxadustat.
-
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
2/28/2022
FibroGen, Inc. reported financial results for the fourth quarter and full year 2021 and provided an update on the company’s recent developments.
-
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
2/14/2022
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close.
-
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
2/4/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST.
-
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
1/4/2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13.
-
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
12/20/2021
FibroGen, Inc. and HiFiBiO Therapeutics announced an extension of their partnership with FibroGen’s exercise of an exclusive license option for HiFiBiO’s anti-CCR8 monoclonal antibody program.
-
FibroGen Reports Third Quarter 2021 Financial Results
11/9/2021
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2021 and provided an update on the Company’s recent developments.
-
GlaxoSmithKline is lining up a potential new treatment for patients with anemia due to chronic kidney disease following positive results in a Phase III study.
-
FibroGen to Present at Upcoming Investor Conferences - Nov 02, 2021
11/2/2021
FibroGen, Inc. announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences.
-
FibroGen to Report Third Quarter 2021 Financial Results
10/26/2021
FibroGen, Inc. will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close.
-
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
10/25/2021
FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 - 7, 2021.
-
The top three clusters from last year's list - Greater Boston, San Francisco Bay Area and San Diego - all stood their ground and maintained their rankings from the previous year.
-
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
8/25/2021
FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
-
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
8/16/2021
FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role.
-
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
8/11/2021
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD).
-
The FDA indicated the drug couldn’t be approved in its present form and asked for another clinical trial of the drug be run before they reapplied.
-
FibroGen Reports Second Quarter 2021 Financial Results
8/9/2021
FibroGen, Inc. reported financial results for the second quarter 2021 and provided an update on the Company’s recent developments.